Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin
Phase 2 – studying effectiveness and dosage
Conditions:
Categoria 2
Patients with vegetable allergies due to sensitization to profilin and LTPs
and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP) has not been effective
were evaluated in a before-after study to assess changes in clinical reactivity to LTP (peach) and profilin (melon) and immunological changes after intervention with omalizumab.
Sponsor: Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud
trial.available_in:
БГ
Overview
Trial status: Authorised
Clinical efficacy defined as an increase in the amounts of at least 1 other food related to sensitisation to LTP (quantitative)., Clinical efficacy defined as an increase in the amounts of at least 1 more food related to sensitisation to profilin (quantitative)., Analysis of quality of life before and after treatment with omalizumab.
Clinical efficacy defined as an increase in the amounts of peach in patients allergic to LTP and melon in patients allergic to apple tolerated in PPO after 16 weeks of treatment with omalizumab.
Description
Clinical efficacy defined as an increase in the amounts of at least 1 other food related to sensitisation to LTP (quantitative)., Clinical efficacy defined as an increase in the amounts of at least 1 more food related to sensitisation to profilin (quantitative)., Analysis of quality of life before and after treatment with omalizumab.
Who can participate
Age group: 18-64 years, 0-17 years
Gender: Female, Male
Target enrollment: 37 participants
Interventions
Omlyclo 75 mg solution for injection in pre-filled syringe
БГ